Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report
Related Experiment Video
Updated: Jul 15, 2026
Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
Kristofoor E Leeuwenberg1, Rob Ter Heine2, Johanna M M Gijtenbeek1
1Department of Neurology, Radboud Research Institute for Medical Innovation, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.
Introduction:
Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.
Case Presentation:
We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.
Conclusion:
Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.
Insights
Adagrasib, a new cancer drug, may cause polyradiculitis, a rare neurological side effect. Early recognition and dose adjustment can manage this complication while maintaining tumor response.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Adagrasib is a targeted therapy for KRAS G12C-mutated cancers.
- Neurological adverse events associated with adagrasib are reportedly uncommon.
Observation:
- A 70-year-old woman developed polyradiculitis during adagrasib treatment.
- Symptoms resolved with prednisone and adagrasib dose modification.
Findings:
- This case represents the first reported instance of adagrasib-induced polyradiculitis.
- Adagrasib dose reduction maintained therapeutic serum concentrations and anti-tumor efficacy.
Implications:
- Clinicians should consider polyradiculitis as a potential adverse event of adagrasib.
- Awareness of this side effect is crucial for managing patients on adagrasib therapy.
